Table 3 Pharmacological intervention for GCX protection
From: Glycocalyx and its involvement in clinical pathophysiologies
Authors | Study subjects | Substances | Insults | Results |
|---|---|---|---|---|
Broekhuizen [67] | Patients | Sulodexide | Diabetes mellitus type 2 | GCX thickness increased |
Gao [71] | Rats | Hydrocortisone | Pancreatitis | Improved intestinal perfusion Attenuation of Syn-1 and HA release |
Nordling [72] | Endothelial cells | Immobilized heparin conjugate | IRI | Attenuation of thrombotic disorder |
Strunden [75] | Isolated mouse lung | HES | Heparinase | HES attenuated interstitial edema, increased pulmonary arterial pressure |
Chappell [70] | Isolated guinea pig heart | Corticosteroid | IRI | Increase in Syn-1 and reduction in HS |
Chappell [79] | Isolated guinea pig heart | Sevoflurane | IRI | Increase in Syn-1 and reduction in HS |